Dana Gerberi

Dana Gerberi

Auto-generated profile, based on publicly available information

Dana Gerberi

Mayo Clinic Libraries Mayo Clinic Rochester Minnesota USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2021 in Clinical Gerontologist
Verified
Journal Article
Closed access
ESEvelina Sterina
Evelina Sterina
AHAdriana P. Hermida
Adriana P. Hermida
DGDanielle J. Gerberi
Danielle J. Gerberi
MLMaria I Lapid
Maria I Lapid
To examine post-traumatic stress, depression, anxiety, and well-being in older adults under quarantine.A systematic review of CINAHL, Ovid EBM Reviews, Ovid Embase, Ovid Medline, Ovid PsycINFO, Sco...

31 October 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
JLJonathan G Leung
Jonathan G Leung
LZLusi Zhang
Lusi Zhang
MMMatej Markota
Matej Markota
VEVicki L. Ellingrod
Vicki L. Ellingrod
DGDanielle J. Gerberi
Danielle J. Gerberi
JBJeffrey R Bishop
Jeffrey R Bishop

1 February 2021 in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Verified
Journal Article
Open access
ITImad Tleyjeh
Imad Tleyjeh
ZKZakariya Kashour
Zakariya Kashour
OAOweida AlDosary
Oweida AlDosary
MRMuhammad Riaz
Muhammad Riaz
HTHaytham Tlayjeh
Haytham Tlayjeh
TKTarek Kashour
Tarek Kashour
To systematically review the literature and estimate the risk of Chloroquine (CQ) and hydroxychloroquine (HCQ) cardiac toxicity in COVID-19 patients. We searched multiple data sources including PubMed/MEDLINE, Ovid Embase, Ovid EBM Reviews, Scopus, and Web of Science, and medrxiv.org from November 2019 through May 27, 2020. We included studies that enrolled COVID-19 patients treated with CQ or HCQ, with or without azithromycin and reported on cardiac toxicities. We performed a meta-analysis using the arcsine transformation of the different incidences. A total of 19 studies with a total of 5652 patients were included. The pooled incidence of TdP arrhythmia or VT or cardiac arrest was 3 per 1000, 95% CI (0-21), I2=96%, 18 studies with 3725 patients. Among 13 studies of 4334 patients, the pooled incidence of discontinuation of CQ or HCQ due to prolonged QTc or arrhythmias was 5%, 95% CI (1-11), I2=98%. The pooled incidence of change in QTc from baseline of ≥ 60 ms or QTc ≥ 500 ms was 9%, 95% CI (3-17), I2=97%. Mean/median age, coronary artery disease, hypertension, diabetes, concomitant QT prolonging medications, ICU care, and severity of illness in the study populations explained between-studies heterogeneity. Treatment of COVID-19 patients with CQ or HCQ is associated with a significant risk of drug-induced QT prolongation and relatively higher incidence of TdP/VT/cardiac arrest. Therefore, these agents should not be used routinely in the management of COVID-19 disease. COVID-19 patients who are treated with antimalarials for other indications should be adequately monitored.

29 May 2022 in Cureus
Verified
Journal Article
Open access
JHJoya-Rita Hindy
Joya-Rita Hindy
Juan A Quintero-MartinezJuan A Quintero-Martinez
Juan A Quintero-Martinez
ALAlexander T. Lee
Alexander T. Lee
CSChristopher Scott
Christopher Scott
DGDanielle J. Gerberi
Danielle J. Gerberi
LBLarry M. Baddour
Larry M. Baddour
Objectives: To determine incidence trends of Staphylococcus aureus bacteremia (SAB) from population-based studies from multiple countries. Methods: A contemporary systematic review was conducted using Ovid Cochrane Central Register of Controlled Trials (1991+), Ovid Embase (1974+), Ovid Medical Literature Analysis and Retrieval System Online (MEDLINE) (1946+ including epub ahead of print, in-process & other non-indexed citations), and Web of Science Core Collection (Science Citation Index Expanded 1975+ and Emerging Sources Citation Index 2015+). Two authors (J.R.H. and J.A.Q.M.) independently reviewed all studies and included those that reported population-based incidence of SAB in patients aged 18 years and older. Results: Twenty-six studies met inclusion criteria with the highest number (n=6) of studies conducted in Canada. The incidence of SAB ranged from 9.3 to 65 cases/100,000/year. The median age of patients with SAB ranged from 62 to 72 years and SAB cases were more commonly observed in men than in women. The most common infection sources were intravascular catheters and skin and soft tissue infections. SAB incidence trends demonstrated high variability for geographic regions and calendar years. Overall, there was no change in the incidence trend across all studies during the past two decades. Conclusion: Multiple factors, both pros, and cons are likely responsible for the overall stable SAB incidence in countries included in this systematic review. Some of these factors vary in geographic location and prompt additional investigations from countries not included in the current review so that a more global characterization is defined.

11 December 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
SHSara F. Haddad
Sara F. Haddad
DDDaniel C. DeSimone
Daniel C. DeSimone
SCSupavit Chesdachai
Supavit Chesdachai
DGDanielle J. Gerberi
Danielle J. Gerberi
LBLarry M. Baddour
Larry M. Baddour
Blood cultures have been the gold standard for identifying pathogens in infective endocarditis (IE). Blood culture-negative endocarditis (BCNE), however, occurs in 40% or more of IE cases with the bulk of them due to recent antibiotic exposure prior to obtaining blood cultures. Increasingly, molecular techniques are being used for pathogen identification in cases of BCNE and more recently has included metagenomic next-generation sequencing (mNGS). We therefore performed a literature search on August 31, 2022, that assessed the mNGS in IE and 13 publications were identified and included in a systematic review. Eight (61.5%) of them focused only on IE with mNGS performed on cardiac valve tissue in four studies, plasma in three studies and cardiac implantable electronic devices (CIED) in one study. Gram-positive cocci, including Staphylococcus aureus (n = 31, 8.9%), coagulase-negative staphylococci (n = 61, 17.6%), streptococci (n = 130, 37.5%), and Enterococcus faecalis (n = 23, 6.6%) were the predominant organisms identified by mNGS. Subsequent investigations are needed to further define the utility of mNGS in BCNE and its impact on patient outcomes. Despite some pitfalls, mNGS seems to be of value in pathogen identification in IE cases, particularly in those with BCNE. This study was registered and on the Open Science Framework platform.

2 October 2023 in Bioengineering
Verified
Journal Article
Open access
PDF file
JGJuan P. Garcia-Mendez
Juan P. Garcia-Mendez
Amos LalAmos Lal
Amos Lal
SHSvetlana Herasevich
Svetlana Herasevich
ATAysun Tekin
Aysun Tekin
YPYuliya Pinevich
Yuliya Pinevich
Vitaly HarsevichVitaly Harsevich
Vitaly Harsevich
Pulmonary auscultation is essential for detecting abnormal lung sounds during physical assessments, but its reliability depends on the operator. Machine learning (ML) models offer an alternative by automatically classifying lung sounds. ML models require substantial data, and public databases aim to address this limitation. This systematic review compares characteristics, diagnostic accuracy, concerns, and data sources of existing models in the literature. Papers published from five major databases between 1990 and 2022 were assessed. Quality assessment was accomplished with a modified QUADAS-2 tool. The review encompassed 62 studies utilizing ML models and public-access databases for lung sound classification. Artificial neural networks (ANN) and support vector machines (SVM) were frequently employed in the ML classifiers. The accuracy ranged from 49.43% to 100% for discriminating abnormal sound types and 69.40% to 99.62% for disease class classification. Seventeen public databases were identified, with the ICBHI 2017 database being the most used (66%). The majority of studies exhibited a high risk of bias and concerns related to patient selection and reference standards. Summarizing, ML models can effectively classify abnormal lung sounds using publicly available data sources. Nevertheless, inconsistent reporting and methodologies pose limitations to advancing the field, and therefore, public databases should adhere to standardized recording and labeling procedures.